KV Pharmaceutical Announces FDA Approval For Morphine ER 100 Mg And 200 Mg Tablets

KV Pharmaceutical Company (NYSE: KVa/KVb) announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its application for the 100 mg and 200 mg strengths of Morphine ER Tablets (MS Contin(R) marketed by Purdue Pharma L.P.). This approval now allows ETHEX Corporation, KV’s wholly-owned generic/non-branded subsidiary, to offer a full line of all strengths of this product. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on October 26th, 2007